Follow
Filippo Baldacci
Filippo Baldacci
Medical Doctor, Department of Clinical and Experimental Medicine, Neurology Unit, University of Pisa
Verified email at unipi.it
Title
Cited by
Cited by
Year
A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer's disease
H Hampel, F Caraci, AC Cuello, G Caruso, R Nisticò, M Corbo, F Baldacci, ...
Frontiers in immunology 11, 456, 2020
2432020
Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease
M Poletti, D Frosini, C Pagni, F Baldacci, V Nicoletti, G Tognoni, C Lucetti, ...
Journal of Neurology, Neurosurgery & Psychiatry 83 (6), 601-606, 2012
2032012
Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study
B Dubois, S Epelbaum, F Nyasse, H Bakardjian, G Gagliardi, ...
The Lancet Neurology 17 (4), 335-346, 2018
2002018
Randomized trial on the effects of a combined physical/cognitive training in aged MCI subjects: the Train the Brain study
Scientific Reports 7 (1), 39471, 2017
1502017
Revolution of Alzheimer precision neurology. Passageway of systems biology and neurophysiology
H Hampel, N Toschi, C Babiloni, F Baldacci, KL Black, ALW Bokde, ...
Journal of Alzheimer's Disease 64 (s1), S47-S105, 2018
1492018
Nuove osservazioni sul problema della Falda Toscana e sulla interpretazione dei flysch arenacei tipo “Macigno” dell’Appennino settentrionale
F Baldacci
Memorie della Società Geologica Italiana 6 (2), 213, 1967
1441967
Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease
A Vergallo, L Mégret, S Lista, E Cavedo, H Zetterberg, K Blennow, ...
Alzheimer's & Dementia 15 (6), 764-775, 2019
1402019
A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs
M Poletti, C Logi, C Lucetti, P Del Dotto, F Baldacci, A Vergallo, M Ulivi, ...
Journal of clinical psychopharmacology 33 (5), 691-694, 2013
1092013
Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer’s disease and other neurodegenerative diseases
F Baldacci, S Lista, E Cavedo, U Bonuccelli, H Hampel
Expert review of proteomics 14 (4), 285-299, 2017
992017
Precision pharmacology for Alzheimer’s disease
H Hampel, A Vergallo, LF Aguilar, N Benda, K Broich, AC Cuello, ...
Pharmacological research 130, 331-365, 2018
972018
Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ1–42, total-tau, phosphorylated-tau, NFL …
H Hampel, N Toschi, F Baldacci, H Zetterberg, K Blennow, I Kilimann, ...
Alzheimer's & Dementia 14 (4), 492-501, 2018
952018
Omics sciences for systems biology in Alzheimer’s disease: State-of-the-art of the evidence
H Hampel, R Nisticò, NT Seyfried, AI Levey, E Modeste, P Lemercier, ...
Ageing Research Reviews 69, 101346, 2021
942021
Progression of brain atrophy in the early stages of Parkinson's disease: A longitudinal tensor‐based morphometry study in de novo patients without cognitive impairment
C Tessa, C Lucetti, M Giannelli, S Diciotti, M Poletti, S Danti, F Baldacci, ...
Human brain mapping 35 (8), 3932-3944, 2014
922014
Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints
E Cavedo, PA Chiesa, M Houot, MT Ferretti, MJ Grothe, SJ Teipel, S Lista, ...
Alzheimer's & Dementia 14 (9), 1204-1215, 2018
872018
Migraine features in migraineurs with and without anxiety–depression symptoms: A hospital-based study
F Baldacci, C Lucchesi, M Cafalli, M Poletti, M Ulivi, M Vedovello, ...
Clinical neurology and neurosurgery 132, 74-78, 2015
782015
Levodopa response in dementia with lewy bodies: a 1-year follow-up study
C Lucetti, C Logi, P Del Dotto, C Berti, R Ceravolo, F Baldacci, C Dolciotti, ...
Parkinsonism & related disorders 16 (8), 522-526, 2010
762010
Low cognitive awareness, but not complaint, is a good marker of preclinical Alzheimer’s disease
F Cacciamani, C Tandetnik, G Gagliardi, H Bertin, MO Habert, H Hampel, ...
Journal of Alzheimer's Disease 59 (2), 753-762, 2017
682017
α-Synuclein heterocomplexes with β-amyloid are increased in red blood cells of Parkinson’s disease patients and correlate with disease severity
S Daniele, D Frosini, D Pietrobono, L Petrozzi, A Lo Gerfo, F Baldacci, ...
Frontiers in Molecular Neuroscience 11, 53, 2018
612018
Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease
S Lista, N Toschi, F Baldacci, H Zetterberg, K Blennow, I Kilimann, ...
Neurochemistry international 108, 355-360, 2017
582017
Fatigue, sleep–wake pattern, depressive and anxiety symptoms and body-mass index: analysis in a sample of episodic and chronic migraine patients
C Lucchesi, F Baldacci, M Cafalli, E Dini, L Giampietri, G Siciliano, S Gori
Neurological Sciences 37, 987-989, 2016
532016
The system can't perform the operation now. Try again later.
Articles 1–20